Riskpilot← Back to searchSign inGet full accessOne-carbon Therapeutics AB
ABActiveOrg 5592135122Fogdevreten 2Research and experimental development on natural sciences and engineering · NACE 7210Est. 20193 employees
Revenue 2024
SEK 0
EBITDA margin
—
-239% vs 2023
Equity ratio
95.7%
Financial strength
Net profit 2024
SEK -21,3M
-228% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -21,8M | -239% |
| Net profit | SEK -21,3M | -228% |
| Total assets | SEK 68,6M | +311% |
| Equity | SEK 65,6M | +854% |
| Employees | 3 | — |
Legal name
One-carbon Therapeutics AB
Org number
5592135122
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
30 juli 2019
Share capital
SEK 250 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas var för sig av Helleday, Thomas Ulf Edvard Lindmark, Emil Gustav André Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva forskning, utveckling och kommersialisering av medicinska produkter och därmed förenlig verksamhet.
Address
Fogdevreten 2
Email
emil.lindmark@one-carbon.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −4 | −211 | −1 106 | −6 414 | −21 769 |
| Depreciation & amort. | −0 | −850 | −0 | −0 | −0 |
| EBIT | −4 | −1 061 | −1 106 | −6 414 | −21 769 |
| Net financials | — | −123 | −398 | −68 | 512 |
| Profit before tax | −4 | −1 184 | −1 504 | −6 482 | −21 257 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −4 | −1 184 | −1 504 | −6 482 | −21 257 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 898 | 11 020 | 9 050 | 16 675 | 68 552 |
| Equity | 46 | 4 862 | 3 359 | 6 877 | 65 620 |
| Long-term debt | 0 | 5 101 | 5 509 | 0 | 0 |
| Short-term debt | 851 | 1 057 | 182 | 9 799 | 2 932 |
| Total debt | 851 | 6 158 | 5 691 | 9 799 | 2 932 |
EBITDA margin
-2176900000.0%
This company
15.8%
Market median
-13777848201% vs market
20202024
Equity ratio
95.7%
This company
38.2%
Market median
+151% vs market
20202024
Return on equity
-32.4%
This company
18.4%
Market median
-276% vs market
20202024
Net profit margin
-2125700000.0%
This company
8.1%
Market median
-26243209977% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AS Chief Executive Officer | Chief Executive Officer | 2025 |
PE Chief Auditor | Chief Auditor | 2026 |
| Former (3) | ||
HT Chief Auditor | Chief Auditor | 2020 – 2020 |
TE Chief Auditor | Chief Auditor | 2021 – 2026 |
JG Chief Executive Officer | Chief Executive Officer | 2020 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2021 | |
| Board of Directors | 2024 | |
| Chairman | 2025 | |
| Former (5) | ||
| Deputy Board Member | 2020 – 2021 | |
| Chairman | 2020 – 2020 | |
| Board of Directors | 2020 – 2020 | |
| Board of Directors | 2021 – 2022 | |
| Chairman | 2021 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of One-carbon Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Thomas Peter Jönsson | Chief Auditor | 0 companies |
| Tobias Eduard Berglund | Chief Auditor | 0 companies |
| Ana Slipicevic | Chief Executive Officer | 0 companies |
| Petter Erik Gustafsson | Chief Auditor | 0 companies |
| Jan Gustaf Zetterberg | Chief Executive Officer | 0 companies |
| Olof Håkan Nordlander | Deputy Board Member | 0 companies |
| Thomas Ulf Edvard Helleday | Board of Directors | 0 companies |
| Ulrika Kristina Berglund | Chairman | 0 companies |
| Marianne Catharina Svanborg | Board of Directors | 0 companies |
| Alexander Mata | Board of Directors | 0 companies |
| Emil Gustav André Lindmark | Board of Directors | 0 companies |
| Gunnar Magnus Severus Persson | Chairman | 0 companies |
| Antoine Jean Prosper Yver | Chairman | 0 companies |